研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

甲状腺乳头状癌与桥本氏病共存的手术治疗:单中心回顾性队列研究。

Surgical management of papillary thyroid carcinoma coexisting with Hashimoto's disease: a single-center retrospective cohort study.

发表日期:2024
作者: Dongdong Zhang, Jixiang Wu, Lin Chen
来源: Frontiers in Endocrinology

摘要:

桥本氏病(HT)对甲状腺乳头状癌(PTC)患者的机制和影响仍然是一个持续争论的话题。对于低危 PTC 病例,甲状腺切除的最佳范围也存在争议。为了探讨 PTC 合并 HT 患者不同手术切除范围的临床结果和预后,我们回顾性分析了 PTC 合并 HT 患者的临床特征和治疗数据。 2014年12月至2023年8月期间在北京大学国际医院接受肺叶切除+峡部切除和甲状腺全切除术的PTC合并HT患者的结局。A组21例患者接受了肺叶切除+峡部切除+预防性中央颈清扫术,而20例患者接受了甲状腺叶切除+峡部切除+预防性中央颈清扫术。 B 组患者接受全甲状腺切除术并预防性中央淋巴结 (LN) 清扫术,但一名未接受 LN 清扫术的患者除外。 A 组的手术时间较短(105.75 分钟 ± 29.35 对比 158.81 分钟 ± 42.01,p = 0.000),术后第 1 天甲状旁腺激素 (PTH) 水平较高 [26.96 pg/ml (20.25, 35.45) 对比 9.01 pg/ml (2.48, 10.93), p = 0.000] 且术后住院时间较短[2.95 d (2.0, 4.0) vs. 4.02 d (3.0, 5.0), p = 0.008] 均较B组短,差异有统计学意义。两组在 PTH [32.10 pg/ml (22.05, 46.50) vs. 20.47 pg/ml (9.43, 34.03), p = 0.192] 和血清钙 (2.37 mmol/L ± 0.06 vs. 2.29 mmol) 方面表现出相似的恢复模式/L ± 0.19,p = 0.409)术后 1 个月后。根据Kaplan-Meier曲线,A组(100%)和B组(97.1%)患者的5年无病生存率无显着差异(Logrank检验:p = 0.420,Breslow检验:p = 0.420)。对于低危PTC合并HT的患者,肺叶切除术联合峡部切除术和预防性中央颈清扫术是一种安全可行的治疗选择。http://www.chictr.org.cn,标识符ChiCTR2300079115。Copyright © 2024张、吴、陈。
The mechanism and impact of Hashimoto's disease (HT) in patients with papillary thyroid carcinoma (PTC) remains a subject of ongoing debate. The optimal extent of thyroid resection is also controversial in cases of low-risk PTC.To investigate the clinical outcomes and prognoses associated with different extents of surgical resection in patients diagnosed with PTC coexisting with HT.We retrospectively analyzed data on the clinical features and treatment outcomes of patients with PTC concomitant with HT who underwent lobectomy with isthmusectomy and those who underwent total thyroidectomy at Peking University International Hospital between December 2014 and August 2023.Twenty-one patients in group A underwent lobectomy with isthmusectomy and prophylactic central neck dissection, whereas twenty patients in group B underwent total thyroidectomy with prophylactic central lymph node (LN) dissection, except one who did not undergo LN dissection. Group A demonstrated shorter surgery time (105.75 min ± 29.35 vs. 158.81 min ± 42.01, p = 0.000), higher parathyroid hormone (PTH) levels on postoperative day 1 [26.96 pg/ml (20.25, 35.45) vs. 9.01 pg/ml (2.48, 10.93), p = 0.000] and a shorter postoperative hospital stay [2.95 d (2.0, 4.0) vs. 4.02 d (3.0, 5.0), p = 0.008] than those of group B, with statistically significant differences. Both groups exhibited similar recovery patterns in terms of PTH [32.10 pg/ml (22.05, 46.50) vs. 20.47 pg/ml (9.43, 34.03), p = 0.192] and serum calcium (2.37 mmol/L ± 0.06 vs. 2.29 mmol/L ± 0.19, p = 0.409) after 1 montsh following the surgery. According to the Kaplan-Meier curves, no significant difference in the 5-year disease-free survival rates were observed between patients in group A (100%) and group B (97.1%) (Log rank test: p = 0.420, Breslow test: p = 0.420).Lobectomy with isthmusectomy and prophylactic central neck dissection is a safe and feasible treatment option for patients with low-risk PTC coexisting with HT.http://www.chictr.org.cn, identifier ChiCTR2300079115.Copyright © 2024 Zhang, Wu and Chen.